Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
This protein carries a human IgG1 Fc fragment at the C-terminus. The protein has a calculated MW of 56.3 kDa. The protein migrates as 60-80 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human CD19 Protein, Fc Tag, primary amine labeling on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Immobilized FMC63 at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD19 Protein, Fc Tag, primary amine labeling (Cat. No. CD9-H8259) with a linear range of 0.039-0.625 μg/mL (QC tested).
Immobilized a series of concentration of Biotinylated Human CD19 Protein, Fc Tag, primary amine labeling (Cat. No. CD9-H8259) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind FMC63 (Mouse IgG2a) 2 μg/mL (100 μL/well) with a linear range of 0.039-1.25 μg/mL (Routinely tested).
Price(USD) : $385.00
Price(USD) : $1670.00
Price(USD) : $32.00
Price(USD) : $137.00
Price(USD) : $50.00
Price(USD) : $120.00
Price(USD) : $138.00
Price(USD) : $230.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tafasitamab | MOR-00208; XmAb-5574; MOR-208; XENP-5574 | Approved | Xencor Inc | MONJUVI, Minjuvi | United States | Lymphoma, Large B-Cell, Diffuse | Morphosys Us Inc | 2020-07-31 | Lymphoma, Large B-Cell, Diffuse; Graft vs Host Disease; Hemic and Lymphatic Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Tisagenlecleucel | LG-740; CART-019; CTL-019; CART-19 | Approved | Novartis Pharma Ag, University Of Pennsylvania | Kymriah | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Novartis Pharmaceuticals Corp | 2017-08-30 | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Central Nervous System Lymphoma | Details |
Axicabtagene ciloleucel | FKC-876; KTE-C19; KTE C19 | Approved | Cabaret Biotech | Yescarta, 奕凯达 | United States | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, B-Cell | Kite Pharma Eu Bv | 2017-10-18 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
Inaticabtagene Autoleucel | CNCT19; CNCT-19; HY001 | Approved | Juventas Cell Therapy Ltd | 源瑞达 | Mainland China | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Juventas Cell Therapy Ltd | 2023-11-08 | Hematologic Neoplasms; Lymphoma, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Hemolytic, Autoimmune; Lupus Erythematosus, Systemic; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
Inebilizumab | MT-0551; VIB-0551; 16C4-aFuc; MEDI-551 | Approved | Duke University, Horizon Therapeutics PLC | Uplizna, ユプリズナ, Uplinza, 昕越 | United States | Neuromyelitis Optica | Viela Bio Inc | 2020-06-11 | Hematologic Neoplasms; Lymphoma, B-Cell; Rejection of renal transplantation; Myasthenia Gravis; Immunoglobulin G4-Related Disease; Scleroderma, Systemic; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Multiple Sclerosis; Neuromyelitis Optica; Leukemia, B-Cell; Encephalitis; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Relmacabtagene autoleucel | JWCAR-029 | Approved | Jw Therapeutics (Shanghai) Co Ltd | 倍诺达, Carteyva | Mainland China | Lymphoma, Large B-Cell, Diffuse | Jw Therapeutics (Shanghai) Co Ltd | 2021-09-01 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Loncastuximab tesirine | MT-2111; ADCT-402 | Approved | Adc Therapeutics Sa | ZYNLONTA, Lonca | United States | Lymphoma, Large B-Cell, Diffuse | Adc Therapeutics Sa | 2021-04-23 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoproliferative Disorders; Waldenstrom Macroglobulinemia; Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Actalycabtagene autoleucel | NexCAR19; HCAR19 | Approved | ImmunoACT Ltd | India | Leukemia | ImmunoACT Ltd | 2023-10-13 | Lymphoma, B-Cell; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Blinatumomab | BiTE-MT-103; bscCD19xCD3; AMG-103; MT-103; MEDI-538 | Approved | Micromet Inc | Blincyto, 倍利妥 | United States | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Amgen Inc | 2014-12-03 | Leukemia; Leukemia, Myelogenous, Chronic; Neoplasm, Residual; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Brexucabtagene autoleucel | KTE-X19; FKC-889 | Approved | Tecartus | United States | Lymphoma, Mantle-Cell | Kite Pharma Inc | 2020-07-24 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Lisocabtagene maraleucel | Liso-Cel; JCAR-017; JCAR017; BMS-986387 | Approved | Juno Therapeutics Inc | Breyanzi | United States | Lymphoma, Large B-Cell, Diffuse | Bristol-Myers Squibb Company | 2021-02-05 | Lymphoma, B-Cell; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Mediastinal Neoplasms; Immune System Diseases; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) | Phase 3 Clinical | Chaim Sheba Medical Center At Tel Hashomer | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
Anti-CD19 CAR T-cell therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Lymphoma, B-Cell | Details | |
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) | Phase 3 Clinical | Wuhan Si'an Medical Technology Co Ltd, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Obexelimab | XmAb-5871; AMG-729 | Phase 3 Clinical | Xencor Inc | Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic | Details |
CD19 CAR-T cell therapy (National University of Malaysia) | Phase 3 Clinical | National University Of Malaysia | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell | Details | |
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | Details |
CAR-T 19 cell therapy (University of Pennsylvania) | Phase 2 Clinical | University Of Pennsylvania | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CLIC-1901 (Ottawa Hospital Research Institute) | CLIC-1901 | Phase 2 Clinical | Ottawa Hospital Research Institute | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
AUTO-3 | AUTO-3 | Phase 2 Clinical | University College London | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
GC-007g | GC007g; GC-007g | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
GNR-084 | GNR-084 | Phase 2 Clinical | Generium Pharmaceuticals, Iontas | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 CAR-T cell therapy (Sinobioway) | Phase 2 Clinical | Sinobioway Biomedicine Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma | Details | |
Evoncabtagene pazurgedleucel | CTX-110 | Phase 2 Clinical | Crispr Therapeutics Ag | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy | GC-197 | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
CD19 CAR-T cell therapy (Chongqing Precision Biotech) | MC-1-50 | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Lymphoma, B-Cell; Leukemia; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Dermatomyositis; Lymphoma, Large B-Cell, Diffuse; Sjogren's Syndrome; Scleroderma, Systemic; Lupus Erythematosus, Systemic; Leukemia, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) | Phase 2 Clinical | Shanghai Zhongshan Hospital, Hrain Biotechnology Co Ltd | Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular | Details | |
BZ019 | BZ-019 | Phase 2 Clinical | Shanghai Cell Therapy Group Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma | Details |
TAK-007 | TAK-007 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, Non-Hodgkin | Details |
CART-19 cells (Henan Hualong Biotechnology) | Phase 2 Clinical | Henan Hualong Biotechnology | Leukemia, Lymphoid | Details | |
pCAR-19B | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) | ORGCAR19; ORGCAR-19 | Phase 2 Clinical | Kecellitics Biotech Company Ltd | Lymphoma, B-Cell; Leukemia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details |
α/β CD3+/CD19+ cell depleted stem cell therapy (Mitchell Cairo) | Phase 2 Clinical | New York Medical College | Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Thrombocytopenia; Lymphoma, Non-Hodgkin; Kostmann Syndrome; Anemia, Sickle Cell | Details | |
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-19 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details |
Chimeric antigen receptor-modified autologous T cell injection targeting CD19 (Bio-gene) | BG-19; BG-19C; BG-T19 | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
GC-022 | GC-022; GC-022F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 2 Clinical | The First Affiliated Hospital Of Nanchang University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details | |
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CAR-CD19 T cell therapy | Phase 2 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) | XLCART-001 | Phase 2 Clinical | Nanjing Medical University | Lymphoma, B-Cell | Details |
Anti CD19 chimeric antigen receptor T cell therapy (YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) | Phase 2 Clinical | Xuanwu Hospital Of Capital Medical University | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
IM19 chimeric antigen receptor T cell therapy | IM19 | Phase 2 Clinical | Beijing Yimiao Medical Technology Co Ltd | Leukemia; Hematologic Neoplasms; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma | Details |
CD19.CAR T Cells (Heidelberg University Hospital) | Phase 2 Clinical | Heidelberg University Hospital | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh | Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation | Details | |
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) | Phase 2 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Hematologic Diseases; Lymphoma, B-Cell | Details | |
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University, Suzhou University | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) | Phase 2 Clinical | University Of Alberta | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
GC-012F | GC-012F; GC012F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, Large B-Cell, Diffuse | Details |
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) | CARCIK-CD19; CIK-CAR.CD19 | Phase 2 Clinical | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
TC-110 | TC-110 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
3rd-gen-CD19-CAR | 3rd-gen-CD19-CAR | Phase 2 Clinical | Bluebird Bio Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
HuCART19 | Phase 2 Clinical | National Cancer Institute | Lymphoma, B-Cell; Rejection of renal transplantation; Renal Insufficiency; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic | Details | |
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital | Leukemia | Details | |
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) | ssCART-19 | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Leukemia; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
CD19 chimeric antigen receptor T cell therapy (Takara Bio) | TBI-1501 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Takara Bio Inc | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Rapcabtagene autoleucel | YTB-323 | Phase 2 Clinical | Novartis Pharma Ag | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Leukemia; Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) | SENL-B19 | Phase 2 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia; Lymphoma, B-Cell; Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma | Details |
KQ-2003 | KQ2003; KQ-2003 | Phase 2 Clinical | Shanghai Keqi Pharmaceutical Technology Co Ltd | Solid tumours; Multiple Myeloma; POEMS Syndrome | Details |
C-CAR011 | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma | Details | |
ALLO-501 | ALLO-501 | Phase 2 Clinical | Cellectis Sa | Lymphoma, B-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
MB-CART19.1 (Miltenyi Biotec) | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Azercabtagene zapreleucel | PBCAR-0191 | Phase 2 Clinical | Baxalta Incorporated | Hematologic Neoplasms; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin | Details |
Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech) | Phase 2 Clinical | Essen Biotech | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Myositis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Lupus Nephritis; Lupus Erythematosus, Systemic | Details | |
BinD-19 (Shenzhen BinDeBio) | BinD-19 | Phase 2 Clinical | Shenzhen Bindebio Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
U-CART (Shanghai Bioray Laboratory Inc) | Phase 2 Clinical | BRL Medicine Inc | Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Fourth-gen CAR T Cells Targeting CD19/CD22 therapy(Essen Biotech) | Phase 2 Clinical | Essen Biotech | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma; Central Nervous System Lymphoma | Details | |
CD19 Universal CAR-γδ T Cells Therapy(Guangzhou Bio-Gene Technology) | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital | Lupus Erythematosus, Systemic | Details | |
CD19/CD22 Bispecific CAR-T Cell Therapy(Beijing Tongren Hospital) | Phase 2 Clinical | Beijing Tongren Hospital, Cmu | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
IMPT-514 | IMPT-514 | Phase 2 Clinical | ImmPACT Bio USA Inc | Lupus Nephritis; Lupus Erythematosus, Systemic | Details |
Anti-CD19 Autologous CAR-T Cell therapy (920th Hospital) | OlyCAR-019 | Phase 2 Clinical | The 920th Hospital Of Joint Logistics Support Force Of PLA | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
Anti-CD19 CAR-T cells with TNFRS19 transmembrane domain | Phase 2 Clinical | Federal Research Institute of Pediatric Hematology Oncology and Immunology | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19/CD22 CAR-T cell therapy (The First Affiliated Hospital Of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
AT-101 (AbClon) | AT-101 | Phase 2 Clinical | Abclon Inc | Hematologic Neoplasms; Lymphoma, Non-Hodgkin | Details |
CABA-201 | CABA-201 | Phase 2 Clinical | Cabaletta Bio Inc | Myasthenia Gravis; Myositis; Dermatomyositis; Scleroderma, Systemic; Autoimmune Diseases; Lupus Nephritis; Lupus Erythematosus, Systemic; Muscular Diseases | Details |
EB-103 | EB-103 | Phase 2 Clinical | Estrella Biopharma Inc, Eureka Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, AIDS-Related; Lymphoma; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma | Details |
Anti-CD19 CAR-T cell therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Lymphoma, Non-Hodgkin | Details | |
CD19- CD34t metabolically programmed CAR T-cell therapy (Medical University of South Carolina) | Phase 2 Clinical | Medical University Of South Carolina | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
IMPT-314 | IMPT-314 | Phase 2 Clinical | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
Denocabtagene Ciloleucel(Beijing Yongtai Ruike Biotechnology Company) | RC19D2; CAR-T-19-D2; RC19-D2; CAR-T-19-DNR | Phase 2 Clinical | Beijing Yongtai Rec Biotechnology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 UCAR-NK cells(920th Hospital of Joint Logistics Support Force of People's Liberation Army of China) | Phase 2 Clinical | The 920th Hospital Of Joint Logistics Support Force Of PLA | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
BCN-CP01 | BCN-CP01; BCN CP01; BCN-CP-01; GLPG5201; GLPG-5201 | Phase 2 Clinical | CellPoint BV | Leukemia, Lymphocytic, Chronic, B-Cell | Details |
GLPG-5101 | 19-CP-02; GLPG5101; 19CP02 | Phase 2 Clinical | CellPoint BV | Lymphoma, Non-Hodgkin | Details |
Allogenic Anti-CD19 gamma delta CAR-T cell therapy(PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, Non-Hodgkin | Details | |
BRL-201 | BRL-201; PD1-19bbz; PD1-19bbz CAR-T | Phase 2 Clinical | BRL Medicine Inc | Leukemia; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR CD19/79b | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) | Phase 2 Clinical | Kk Women'S And Children'S Hospital | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-targeted chimeric antigen receptor T-cell(Pell Bio-Med Technology) | PL-001 | Phase 2 Clinical | Pell Bio-Med Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Emfizatamab | GNC-038 | Phase 2 Clinical | SystImmune | Solid tumours; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Central Nervous System Lymphoma | Details |
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) | Phase 2 Clinical | Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell | Details | |
ISIKOK-19 | ISIKOK-19 | Phase 2 Clinical | Acibadem University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19-CART (Express 4-1BB, Unicar-Therapy Bio-medicine Technology) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Candidiasis, Vulvovaginal; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Autologous anti-CD19 CAR T cell therapy(Kyverna Therapeutics) | KYV-101 | Phase 2 Clinical | National Institutes Of Health, Kyverna Therapeutics Inc | Myasthenia Gravis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Dermatomyositis; Multiple Sclerosis; Lupus Nephritis; Multiple Sclerosis, Chronic Progressive; Scleroderma, Diffuse | Details |
ALETA-001 | ALETA-001 | Phase 2 Clinical | Aleta BioTherapeutics Inc | Lymphoma, B-Cell; Leukemia; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
Bispecific CD19/22 CAR T cells | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Lymphoma; Lymphoma, Non-Hodgkin | Details | |
UCART019 | UCART-019 | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
NCAR19-T | Phase 2 Clinical | Second Military Medical University Of Chinese People'S Liberation Army | Lymphoma, B-Cell | Details | |
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | 4SCAR19/22 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
19273-4SCAR | 19273-4SCAR | Phase 2 Clinical | Peking University | Lymphoma, B-Cell | Details |
Allogeneic CD-19 CAR-T Cell Therapy | Phase 2 Clinical | Shenzhen University General Hospital | Leukemia; Lymphoma, B-Cell | Details | |
CAR-T-19(Immunotech Biopharm) | CAR-T-19(Immunotech Biopharm) | Phase 2 Clinical | Immunotech Biopharm Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma | Details |
1-A-46 | BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, BioRay Pharmaceutical Co Ltd | Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
ThisCART-19 | ThisCART-19; ThisCART19A; ThisCART19C; ThisCART19B | Phase 2 Clinical | Fundamenta Therapeutics Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, AIDS-Related; Anemia, Hemolytic, Autoimmune; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma | Details |
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) | CT-120 | Phase 2 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
Anbalcabtagene autoleucel | CRC-01 | Phase 2 Clinical | Curocell Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Details |
CD19/CD22 dual-target CAR-T (Yake biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Varnimcabtagene autoleucel | ARI-0001; IMN-003A; IMN-003-A | Phase 2 Clinical | Hospital Clínic De Barcelona, Institut D'Investigacions Biomèdiques August Pi I Sunyer | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma | Details | |
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Lymphoma, B-Cell | Details | |
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) | Phase 2 Clinical | Shanghai Ultra-T Immune Therapeutics Co LTD | Leukemia, B-Cell | Details | |
Prizloncabtagene autoleucel | C-CAR039; C-CAR-039; C CAR 039; EXP-039 | Phase 2 Clinical | Cellular Biomedicine Group Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
Budoprutug | Phase 2 Clinical | ValenzaBio Inc | Glomerulonephritis, Membranous; Nephrosis, Lipoid; Glomerulosclerosis, Focal Segmental | Details | |
CD19-CAR-T2 cell therapy (Nanfang Hospital of Southern Medical University) | Phase 2 Clinical | Nanfang Hospital Of Southern Medical University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute | Details | |
GC019F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
AZD-0486 | TNB-486; AZD-0486; AZD0486 | Phase 2 Clinical | Teneobio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details |
Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology) | Phase 2 Clinical | Beijing Yongtai Rec Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CN-201 | CN-201 | Phase 2 Clinical | Curon Biopharmaceutical Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) | Phase 2 Clinical | Federal Research Institute of Pediatric Hematology Oncology and Immunology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details | |
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details | |
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Candidiasis, Vulvovaginal; Neoplasm, Residual; Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19 CAR-T cell therapy (Uppsala University) | Phase 2 Clinical | Uppsala University | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) | Phase 2 Clinical | Zhejiang University, Innovative Cellular Therapeutics Co Ltd, Kunming Medical University | Lymphoma, B-Cell; Myasthenia Gravis; Lymphoma, Large B-Cell, Diffuse; Neuromyelitis Optica; Leukemia, B-Cell; Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) | yinnuokati-19 | Phase 2 Clinical | Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) | BPX-401 | Phase 2 Clinical | Bellicum Pharmaceuticals Inc, Ospedale Pediatrico Bambino Gesu | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details |
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
CD19 CAR-T (HuaDao CAR-Tcell) | Phase 2 Clinical | Huadao (Shanghai) Biopharma Co Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
JCAR-014 | JCAR-014; JCAR021 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Juno Therapeutics Inc | Lymphoma, B-Cell; Leukemia; Leukemia, Lymphoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Candidiasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
A-319 | A-319 | Phase 1 Clinical | Evive Biotech Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
CD19.CAR-VST | CD19.CAR-VST | Phase 1 Clinical | Baylor College Of Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) | Phase 1 Clinical | Henan Provincial Cancer Hospital | Lymphoma, B-Cell | Details | |
TI-1007 | TI-1007 | Phase 1 Clinical | Tianjin Timmune Biotech Inc | Lymphoma, B-Cell | Details |
ET019003-T Cells | ET-019003 | Phase 1 Clinical | Wuhan Union Hospital, Eureka Therapeutics Inc | Leukemia; Lymphoma | Details |
PCAR-019 (Anke Biotechnology) | Phase 1 Clinical | Anhui Anke Biotechnology (Group) Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Prolymphocytic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) | Phase 1 Clinical | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
PTG-01 | PTG-01 | Phase 1 Clinical | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) | Phase 1 Clinical | Shanghai Jiaotong University, Shanghai General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) | Phase 1 Clinical | Stanford University, Orca Biosystems Inc | Candidiasis, Vulvovaginal; Leukemia, Myelogenous, Chronic; Neoplasm, Residual; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia Chromosome | Details | |
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) | WZTL002-1 | Phase 1 Clinical | The Malaghan Institute Of Medical Research | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | POEMS Syndrome | Details | |
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) | Phase 1 Clinical | Tianjin Mycure Medical Technology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19/CD22 CAR-T cell therapy (Shenzhen BinDeBio) | Phase 1 Clinical | Dehe Biotech Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
K-193 | K-193 | Phase 1 Clinical | Beijing Lvzhu Biological Technology Co Ltd | Lymphoma, B-Cell | Details |
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) | Phase 1 Clinical | Chengdu Yinhe Biomedicine Co Ltd, Beijing Marino Biotechnology Co Ltd | Lymphoma, B-Cell; Glioblastoma | Details | |
H-31970-SAGAN | H-31970-SAGAN | Phase 1 Clinical | Baylor College Of Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
Zeripatamig | NI-1701; TG-1801 | Phase 1 Clinical | Novimmune Sa | Lymphoma, B-Cell | Details |
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) | Phase 1 Clinical | Tianjin Timmune Biotech Inc | Leukemia; Lymphoma, Non-Hodgkin | Details | |
Autologous CD19 CAR+ EGFTt + T cells (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Leukemia, B-Cell | Details | |
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | Phase 1 Clinical | Fujian Medical University | Lymphoma, Large B-Cell, Diffuse | Details | |
CD19-Car T Cell Therapy(City Of Hope National Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center, National Cancer Institute | Lymphoma, B-Cell; Leukemia, Hairy Cell; Lymphomatoid Granulomatosis; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details | |
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) | Phase 1 Clinical | Nagoya University, Shinshu University | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
XYF19 CAR-T Cell Therapy | XYF-19 | Phase 1 Clinical | Guangzhou Yinming Biomedical Technology Co Ltd, Xi'An Yufan Biotechnology Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Vadacabtagene leraleucel | 19-28z CAR T cells; 19-28z+ T cells; JCAR-015; JCAR-15; 19-28z-T-Cells | Phase 1 Clinical | Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Fred Hutchinson Cancer Research Center | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) | Phase 1 Clinical | Juno Therapeutics Inc | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
KD-019 (Nanjing KAEDI Biotech) | KD-C19 (Nanjing KAEDI Biotech) | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Leukemia; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, Non-Hodgkin | Details | |
Humanized CD19 CAR-T cell therapy (Yake) | YK-C19 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 CAR T-cell therapy (University College London) | 4G7-CARD | Phase 1 Clinical | University College London | Central Nervous System Lymphoma | Details |
4-1BBz CD19-Her2tG (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Neoplasms; Lymphoma | Details | |
ICT19G1 | ICT-19G1 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD19- and CD22 specific CAR (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma | Details | |
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 1 Clinical | The First Affiliated Hospital Of Nanchang University | Multiple Myeloma | Details | |
ET-019002 | ET-019002 | Phase 1 Clinical | Eureka Therapeutics Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
MC-19PD1 CAR-T cell therapy (Peking University) | Phase 1 Clinical | Peking University | Lymphoma | Details | |
CC-97540 | CC-97540; BMS-986353 | Phase 1 Clinical | Juno Therapeutics Inc | Myositis; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Multiple Sclerosis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Lymphoma | Details |
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic; Waldenstrom Macroglobulinemia | Details | |
Virus-specific-CD19.CAR | Phase 1 Clinical | Baylor College Of Medicine | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19-CD34 CAR transduced T cell therapy (Loyola University) | Phase 1 Clinical | Loyola University Chicago | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) | Phase 1 Clinical | Aikangd Biomedical Technology (Suzhou) Co Ltd | Leukemia; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Senl-1904A | Senl-1904A; Senl_1904A | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
aCD19z | aCD19z | Phase 1 Clinical | Christie Hospital Nhs Foundation Trust | Lymphoma, Non-Hodgkin | Details |
CD19-STAR-T cell therapy (China Immunotech Co Ltd) | Phase 1 Clinical | Hebei Yanda Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) | Phase 1 Clinical | Kunming Medical University | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
GC-007F (Gracell Biotechnology) | GC-007F | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD22/CD19 monoclonal antibody-toxin conjugate | Phase 1 Clinical | The University Of Texas Southwestern Medical Center | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-CAR(The University Of Texas MD Anderson Cancer Center) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Leukemia; Lymphoma | Details | |
B-019 | B-019 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
KT-030 | KT-030 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
UCART-19 | S-68587; UCART-19 | Phase 1 Clinical | Cellectis Sa | Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Dual CD19/CD20 targeting CAR-T therapy(Poseida Therapeutics) | Phase 1 Clinical | Poseida Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19-CART (Unicar-Therapy Bio-medicine Technology) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 chimeric antigen receptor T cell therapy(TriArm Therapeutics) | Phase 1 Clinical | TriArm Therapeutics (Shanghai) Co Ltd | Hematologic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
CD19-t-haNK | Phase 1 Clinical | Nantkwest Inc, Immunitybio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, Large-Cell, Anaplastic | Details | |
OnCARlytics(Imugene) | CF-33-CD-19 | Phase 1 Clinical | City Of Hope National Medical Center, Imugene Ltd | Solid tumours | Details |
KITE-363 | KITE-363 | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details | |
SYNCAR-001 | SYNCAR-001 | Phase 1 Clinical | Synthekine Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
ATA-3219 | ATA-3219; ATA3219 | Phase 1 Clinical | Atara Biotherapeutics Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Lymphoma, Non-Hodgkin; Lymphoma | Details |
CLN-978 | CLN-978 | Phase 1 Clinical | Adimab LLC | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
SC-291 | SC-291; SC291 | Phase 1 Clinical | Sana Biotechnology Inc | Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lymphoma, B-Cell; Microscopic Polyangiitis; Lupus Erythematosus, Cutaneous; Autoimmune Diseases; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Leukemia, Lymphoid; Central Nervous System Lymphoma | Details | |
LUCAR-G39P | LUCAR-G39P | Phase 1 Clinical | Lymphoma, Non-Hodgkin | Details | |
EGFRt/19-28z/IL-12 CAR T Cells therapy(Roswell Park Cancer Institute) | Phase 1 Clinical | Roswell Park Cancer Institute | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital) | Phase 1 Clinical | Wuhan Union Hospital | Lupus Erythematosus, Systemic | Details | |
SC-U02 | nvGT UCART19; SC-U02 | Phase 1 Clinical | Sunnycell Therapeutics Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy(Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing GoBroad Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine) | FKC-288; FKC288 | Phase 1 Clinical | Nanjing University School Of Medicine | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lupus Nephritis | Details |
CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Lymphoma, B-Cell; Autoimmune Diseases | Details | |
AUTO-1-NG | AUTO-1-NG; AUTO1/22 | Phase 1 Clinical | Autolus Therapeutics Plc, University College London | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details |
Allogeneic Second-generation CD19-CAR T Cells therapy(Bambino Gesu Hospital And Research Institute) | Phase 1 Clinical | Bambino Gesu Hospital And Research Institute | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
4SCAR19U T Cells Therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR19U cells | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
UTAA-09 | UTAA 09/17; UTAA-09; UTAA09; UTAA09/17γδT | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Lymphoma, B-Cell | Details |
QH-103 Cell Therapy | QH-103 | Phase 1 Clinical | Anhui Provincial Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) | Phase 1 Clinical | Massachusetts General Hospital | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details | |
TBI-2001 | TBI-2001 | Phase 1 Clinical | University Health Network, Takara Bio Inc | Lymphoma, B-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
PBCAR19B | PBCAR-19B | Phase 1 Clinical | Baxalta Incorporated, Precision Biosciences Inc | Hematologic Neoplasms; Neoplasms | Details |
IASO-782 | IASO-782; IASO782 | Phase 1 Clinical | Shanghai Xunlu Biotechnology Co Ltd | Purpura, Thrombocytopenic, Idiopathic; Anemia, Hemolytic, Autoimmune; Thrombocytopenia; Anemia, Hemolytic | Details |
Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH) | Phase 1 Clinical | National Cancer Institute | Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19 specific Chimeric Antigen Receptor T Cell therapy(Nationwide Children'S Hospital) | Phase 1 Clinical | Nationwide Children'S Hospital | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details | |
BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma) | SWK001; SWK-001 | Phase 1 Clinical | Hunan Siweikang Pharmaceutical Co Ltd | Multiple Myeloma | Details |
Metabolically Armed CD19 CAR-T cells(Leman Biotech) | Meta10-19 | Phase 1 Clinical | Leman Biotech Co Ltd, Anhui Provincial Hospital | Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CARTHIAE-1 | CARTHIAE-1 | Phase 1 Clinical | Miltenyi Biotec Inc, Hospital Israelita Albert Einstein | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19/CD70 NK cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, Non-Hodgkin | Details | |
CD19-7×19 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
Human CD19 Targeted DASH CAR-T Cells (Hrain Biotechnology) | HR016 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD19-CAR-NK(JD Biotech) | JD-010; JD010 | Phase 1 Clinical | Beijing JD Biotech Co Ltd | Hematologic Neoplasms | Details |
Anti-CD19-CAR T cells (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Leukemia | Details | |
Anti-CD19-CAR γδT cells (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Leukemia; Lymphoma | Details | |
CAR-DC(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, B-Cell | Details | |
CD19-CAR-T cell therapy (China Immunotech/Avalon Globocare) | AVA-001 (Avalon GloboCare); AVA-001 | Phase 1 Clinical | Avalon Globocare Corp | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
CD19 directed CAR T cell therapy (University of Colorado) | Phase 1 Clinical | University Of Colorado | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
U-01 | U-01 | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Leukemia; Leukemia, B-Cell | Details |
ABBV-319 | ABBV-319 | Phase 1 Clinical | Abbvie Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD19-CAR-DNT cells Therapy(Zhejiang Ruijiamei Biotechnologies Co Ltd) | RJMty-19 | Phase 1 Clinical | Zhejiang Ruijiamei Biotechnologies Co Ltd | Lymphoma, B-Cell; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Scleroderma, Systemic; Autoimmune Diseases; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) | Phase 1 Clinical | University Of Colorado | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
Anti-CD19-CAR CMV-specific T-lymphocytes cell therapy (City Of Hope National Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details | |
SNC-103 | SNC-103; SNC103; F01; F-01 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Lymphoma, B-Cell; Autoimmune Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
PIT-565 | PIT-565 | Phase 1 Clinical | Novartis Pharma Ag | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute | Details |
QN-019a | QN-019a | Phase 1 Clinical | Hangzhou Qihan Biotechnology Co Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
Anti-CD19 universal chimeric antigen receptor T cell therapy (BRL Medicine) | BRL-301; CD19-UCART | Phase 1 Clinical | BRL Medicine Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Sjogren's Syndrome; Scleroderma, Systemic; Antiphospholipid Syndrome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
CC-312 | CC-312 | Phase 1 Clinical | CytoCares (Shanghai) Inc | Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CAR-T-19 Cell Therapy (The General Hospital Of The People'S Liberation Army) | Phase 1 Clinical | Pla General Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
Autologous hematopoietic stem cell therapy (YaKe Biotechnology) | Phase 1 Clinical | Zhejiang University, Ningbo Yake Biotechnology Co Ltd | Lymphoma | Details | |
RG-6333 | RO-7443904 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Lymphoma, Non-Hodgkin | Details |
SNUH-CD19-CAR-T Cell Therapy | SNUH-CD19-CAR-T | Phase 1 Clinical | Seoul National University Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
YK-012 | YK012 | Phase 1 Clinical | Lymphoma, B-Cell | Details | |
KUR-502 CD19 CAR-NKT | CMD-502; KUR-502 | Phase 1 Clinical | Baylor College Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CNTY-101 | CNTY-101 | Phase 1 Clinical | Century Therapeutics Llc | Lymphoma, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
TanCART19/20 | Phase 1 Clinical | Pla General Hospital | Neuromyelitis Optica | Details | |
Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) | LNF-1904 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
aT19 (Beijing Yongtai Ruike Biotechnology) | aT19; aT-19 | Phase 1 Clinical | Beijing Yongtai Rec Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
LCAR-AIO | LCAR-AIO; VHH CAR-T | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
GC-502 | GC-502 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) | Phase 1 Clinical | University Of Colorado, Denver, Usa | Lymphoma, Non-Hodgkin | Details | |
CAR-20-19-22 | CAR-20-19-22 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Autologous CAR19 T lymphocytes Therapy | Phase 1 Clinical | Institute of Hematology and Blood Transfusion, Czech Republic | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
MCM-998 | MCM-998; LXG-250 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
Englumafusp alfa | RG-6076; RO-7227166 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Lymphoma, Non-Hodgkin | Details |
FT-596 | FT-596 | Phase 1 Clinical | Fate Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CAR-iNKT cells therapy (North Jiangsu People's Hospital) | Phase 1 Clinical | Affiliated Hospital Of Jiangsu University | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CAR-NK019(Second Affiliated Hospital, School of Medicine, Zhejiang University) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
RGV-004 | RGV-004 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell | Details |
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Primary mediastinal B cell lymphoma | Details | |
CD19 CAR engineered autologous T-cells Therapy(Sabz Biomedicals) | Phase 1 Clinical | Sabz Biomedicals | Leukemia, Biphenotypic, Acute | Details | |
Anti-BCMA/CD19 CAR-T Therapy(University College London) | Phase 1 Clinical | University College London | Multiple Myeloma | Details | |
CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital) | Phase 1 Clinical | Wuhan Union Hospital | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
NKX-019 | NKX-019 | Phase 1 Clinical | Nkarta Inc | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center) | Phase 1 Clinical | University Hospitals Cleveland Medical Center | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
IKS-03 | LCB 73; IKS 03; IKS-03; NI-2201 | Phase 1 Clinical | Legochem Biosciences Inc, Novimmune Sa | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) | HX-s001; YTS101; HX-s001/YTS101; HXYT-001 | Phase 1 Clinical | Beijing Qingyi Taike Pharmaceutical Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 CAR-T Cell Therapy (PersonGen) | Phase 1 Clinical | Persongen Biotherapeutics | Details | ||
CTA-30X | CTA-30X; CTA30X | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
huCART19-IL18 | Phase 1 Clinical | University Of Pennsylvania | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CB-010 | CB-010 | Phase 1 Clinical | Caribou Biosciences Inc | Lymphoma, B-Cell; Lupus Nephritis; Lymphoma; Lymphoma, Non-Hodgkin | Details |
FT-819 | FT-8198; FT-819; FT 8198 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Lymphoma, B-Cell; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
HY-004 (Juventas) | HY-004 (Juventas) | Phase 1 Clinical | Juventas Cell Therapy Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Anti-human CD19-CD22 T cell therapy | HR004 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Central Nervous System Lymphoma | Details |
PBLTT52CAR19 | Phase 1 Clinical | Great Ormond Street Hospital For Children Nhs Foundation Trust | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Murine CD19 CAR-T cell therapy (Yake) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells | TAK-940 | Phase 1 Clinical | Takeda, Memorial Sloan Kettering Cancer Center | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details |
CD19/CD22-Dual-STAR-T cell therapy (Hebei Yanda Ludaopei Hospital) | Phase 1 Clinical | Hebei Yanda Ludaopei Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
GB5005 chimeric antigen receptor T cell therapy (Genbase) | GB-5005 | Phase 1 Clinical | Shanghai Genbase Biotechnology Co Ltd, Shanghai Genechem Co Ltd | Leukemia, B-Cell | Details |
ET190L1-ARTEMIS T cells (Eureka Therapeutics) | ET190L1-ARTEMI; ET-190; ET190L1; ET190 | Phase 1 Clinical | Eureka Therapeutics Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
CLBR-001/SWI-019 | CLBR-001/SWI-019 | Phase 1 Clinical | Abbvie Inc, California Institute For Biomedical Research | Lymphoma, B-Cell | Details |
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) | Phase 1 Clinical | Immune Cell Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CTA-101 | CTA-101 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
ET-02 | ET-02 | Clinical | Edigene Inc | Lymphoma, B-Cell | Details |
PD-1Ab21-CD19CAR-T (CD biopharma) | CD-202; PZ04 | Clinical | Hematologic Neoplasms | Details | |
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) | PZ-01 | Clinical | Pinze Lifetechnology Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
B6I-28Z CAR T cell therapy (The Affiliated Hospital of Xuzhou Medical University) | Clinical | The Affiliated Hospital Of Xuzhou Medical University | Lymphoma, B-Cell | Details | |
BCM-5011 | BCM-5011 | Clinical | ImmuneCyte Inc | Lymphoma, B-Cell | Details |
Anti-CD19 CAR-T Cells (Shaanxi Provincial People'S Hospital) | Clinical | Shaanxi Provincial People'S Hospital | Leukemia, B-Cell | Details | |
4G7SDIE | Clinical | Synimmune Gmbh, University Of Tubingen | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) | Clinical | Leidos | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy(Chinese PLA General Hospital) | The Seventh Medical Center Of Chinese Pla General Hospital | Details | |||
Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) | The Second People Hospital Of Guangdong Province | Details | |||
Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Tongji University) | Tongji University | Details | |||
Anti-CD19 CAR NK Cell therapy (Enricnk) | KN5501; KN-5501 | Nanjing Enricnk Biotech Co Ltd | Details | ||
Cemacabtagene ansegedleucel (Allogene Therapeutics) | ALLO-501A; ALLO-501.1 | Cellectis Sa | Details |
This web search service is supported by Google Inc.